Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.59
(-0.45%)
USD 0.59
(-0.45%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -5.28 USD | -83.33% |
| 2022 | -3.00 USD | 40.0% |
| 2021 | -5.04 USD | 0.0% |
| 2020 | -5.23 USD | 9.09% |
| 2019 | -5.37 USD | 21.43% |
| 2018 | -7.18 USD | 17.65% |
| 2017 | -8.56 USD | -30.77% |
| 2016 | -6.59 USD | 27.78% |
| 2015 | -8.87 USD | 43.75% |
| 2014 | -15.93 USD | -166.67% |
| 2013 | -5.80 USD | -934.48% |
| 2012 | -0.58 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.03 USD | -9.84% |
| 2024 Q2 | -0.02 USD | 14.18% |
| 2023 Q1 | -0.02 USD | -12400.0% |
| 2023 Q2 | -0.03 USD | -11.6% |
| 2023 Q4 | -0.02 USD | 12.19% |
| 2023 Q3 | -0.03 USD | 0.0% |
| 2023 FY | - USD | -83.33% |
| 2022 Q2 | -0.03 USD | -137.39% |
| 2022 Q1 | -0.01 USD | 62.9% |
| 2022 FY | - USD | 40.0% |
| 2022 Q4 | -0.00 USD | 99.21% |
| 2022 Q3 | -0.03 USD | 7.69% |
| 2021 Q3 | -0.03 USD | -36.48% |
| 2021 Q4 | -0.03 USD | 2.52% |
| 2021 FY | - USD | 0.0% |
| 2021 Q2 | -0.02 USD | 4.12% |
| 2021 Q1 | -0.02 USD | 23.58% |
| 2020 FY | - USD | 9.09% |
| 2020 Q3 | -0.03 USD | -1.41% |
| 2020 Q2 | -0.03 USD | -7.98% |
| 2020 Q1 | -0.03 USD | 23.1% |
| 2020 Q4 | -0.03 USD | -10.42% |
| 2019 Q3 | -0.03 USD | -20.09% |
| 2019 Q1 | -0.03 USD | -11.65% |
| 2019 FY | - USD | 21.43% |
| 2019 Q4 | -0.03 USD | -21.71% |
| 2019 Q2 | -0.02 USD | 32.17% |
| 2018 Q4 | -0.03 USD | 0.32% |
| 2018 FY | - USD | 17.65% |
| 2018 Q3 | -0.03 USD | 14.6% |
| 2018 Q1 | -0.04 USD | -13.14% |
| 2018 Q2 | -0.04 USD | 17.31% |
| 2017 Q4 | -0.04 USD | -5.43% |
| 2017 FY | - USD | -30.77% |
| 2017 Q3 | -0.04 USD | 15.01% |
| 2017 Q2 | -0.04 USD | 18.46% |
| 2017 Q1 | -0.05 USD | -137.05% |
| 2016 Q2 | -0.03 USD | 28.06% |
| 2016 Q4 | -0.02 USD | 29.78% |
| 2016 Q3 | -0.03 USD | -13.12% |
| 2016 Q1 | -0.04 USD | -11.68% |
| 2016 FY | - USD | 27.78% |
| 2015 FY | - USD | 43.75% |
| 2015 Q4 | -0.04 USD | 7.14% |
| 2015 Q3 | -0.04 USD | 12.09% |
| 2015 Q2 | -0.04 USD | 40.53% |
| 2015 Q1 | -0.07 USD | 15.54% |
| 2014 Q1 | -0.07 USD | -16.17% |
| 2014 Q4 | -0.09 USD | -5.03% |
| 2014 Q2 | -0.08 USD | -13.47% |
| 2014 FY | - USD | -166.67% |
| 2014 Q3 | -0.08 USD | -7.52% |
| 2013 Q3 | -0.05 USD | -325.23% |
| 2013 Q2 | -0.01 USD | -205.71% |
| 2013 Q1 | -0.00 USD | 62.77% |
| 2013 Q4 | -0.06 USD | -26.37% |
| 2013 FY | - USD | -934.48% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -0.01 USD | -944.44% |
| 2012 Q3 | -0.00 USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -780.0% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 50.515% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | -176.44% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | -188.525% |
| Azitra, Inc. | -54.76 USD | 90.358% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -194.972% |
| Chromocell Therapeutics Corporation | -1.28 USD | -312.5% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -205.202% |
| CEL-SCI Corporation | -0.73 USD | -623.288% |
| iBio, Inc. | -6.50 USD | 18.769% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -4300.0% |
| MAIA Biotechnology, Inc. | -1.49 USD | -254.362% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -794.915% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 96.192% |
| NanoViricides, Inc. | -0.70 USD | -654.286% |
| Oragenics, Inc. | -9.18 USD | 42.484% |
| BiomX Inc. | -5.10 USD | -3.529% |
| BiomX Inc. | -5.10 USD | -3.529% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 4500.0% |
| Palatin Technologies, Inc. | -2.02 USD | -161.386% |
| Scorpius Holdings, Inc. | -347.20 USD | 98.479% |